Physician profile
Robert L Dickson
NPI 1982198594
$3,376.58
in general payments reported to CMS, 2019-2025
27 companies · $962 in 2025
The $962 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.16 · 2021: $314 · 2022: $336 · 2023: $537 · 2024: $1,216 · 2025: $962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,699 · Education: $15.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,699.35 |
| Education | $15.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $653.69 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $554.99 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $405.51 | 2023-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $276.52 | 2021-2025 | |
| Amgen INC. | $221.23 | 2021-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $208.72 | 2021-2025 | Breztri, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $160.27 | 2023-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $113.78 | 2024-2025 | Rexulti |
| Tolmar, INC. | $97.92 | 2024-2025 | Jatenzo |
| Phathom Pharmaceuticals, INC. | $87.20 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $73.43 | 2024-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $58.80 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $55.35 | 2024 | Gvoke Hypopen, Keveyis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.11 | 2024-2025 | Caplyta |
| Scilex Pharmaceuticals INC. | $46.23 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $45.18 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Lundbeck LLC | $33.46 | 2025 | Vyepti |
| Axsome Therapeutics, INC. | $32.23 | 2023-2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $31.68 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $31.18 | 2021 | |
| Boston Scientific Corporation | $28.38 | 2022 | |
| Janssen Pharmaceuticals, INC | $24.71 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.10 | 2025 | |
| Dexcom, INC. | $18.76 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.21 | 2023 | Synjardy, Trijardy Xr, Jardiance |
| Abbott Laboratories | $15.22 | 2024 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $12.72 | 2023 | Livalo, Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.